Eco-friendly micellar electrokinetic capillary chromatographic method for the simultaneous determination of newly developed antiviral agents in pharmaceutical formulations

References

• WHO. Global Health Sector Strategy on Viral Hepatitis 2016-2021 [Internet].World Health Organization. 2016 [cited 19 April 2017]. Available from: http://apps.who.int/iris/bitstream/10665/246177/1/WHO-HIV-2016.06-eng.pdf?ua=1
   Google Scholar
• Li, H.; Lo, S. Hepatitis C Virus: Virology, Diagnosis and Treatment. World J. Hepatol. 2015, 7(10), 1377–1389.
   PubMed Web of Science ®Google Scholar
• EASL. EASL Recommendations on Treatment of Hepatitis C. J. Hepatol. 2015, 63(1), 199–236.
   PubMed Web of Science ®Google Scholar
• Gutierrez, J.; Lawitz, E.; Poordad, F. Interferon-Free, Direct-Acting Antiviral Therapy for Chronic Hepatitis C. J. Viral Hepat. 2015, 22(11), 861–870.
   PubMed Web of Science ®Google Scholar
• Jack, K. Advances in Treatments for Hepatitis C. British J. Healthcare Manage. 2015, 21(9), 408–412.
   Google Scholar
• Majumdar, A.; Kitson, M.; Roberts, S. Treatment of Hepatitis C in Patients with Cirrhosis: Remaining Challenges for Direct-Acting Antiviral Therapy. Drugs. 2015, 75(8), 823–834.
   PubMed Web of Science ®Google Scholar
• Zhang, X. Direct Anti-HCV Agents. Acta Pharm. Sin B. 2016, 6(1), 26–31.
   PubMed Web of Science ®Google Scholar
• Asselah, T.; Boyer, N.; Saadoun, D.; Martinot-Peignoux, M.; Marcellin, P. Direct-Acting Antivirals for the Treatment of Hepatitis C Virus Infection: Optimizing Current IFN-Free Treatment and Future Perspectives. Liver Int. 2016, 36(Suppl 1), 47–57.
   PubMed Web of Science ®Google Scholar
• Wang, Y.; Lv, Z.; Chu, Y. HIV Protease Inhibitors: A Review of Molecular Selectivity and Toxicity. HIV AIDS. 2015, 7(1), 95–104.
   Google Scholar
• Hussaini, T. Paritaprevir/Ritonavir-Ombitasvir and Dasabuvir, the 3D Regimen for the Treatment of Chronic Hepatitis C Virus Infection: A Concise Review. HIV AIDS. 2016, 8(1), 61–68.
   Google Scholar
• A 4-Drug Combination (Viekira Pak) for Hepatitis C. JAMA. 2015, 313(18), 1857–1858. doi:10.1001/jama.2015.4562.
   PubMed Web of Science ®Google Scholar
• US.FDA. FDA Approves Viekira Pak to Treat Hepatitis C 2014 [cited 2016 Sep.26]. Available from: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm427530.htm.
   Google Scholar
• US.FDA. FDA Approves Technivie for Treatment of Chronic Hepatitis C Genotype 4. 2015 [cited 2016 Sep.26]. Available from: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm455857.htm.
   Google Scholar
• Bonfilio, R.; Araujo, M.; Salgado, H. Recent Applications of Analytical Techniques for Quantitative Pharmaceutical Analysis: A Review. WSEAS Trans. Biol. Biomed. 2010, 7(4), 316–338.
   Google Scholar
• Gutleben, W.; Tuan, N.; Stoiber, H.; Dierich, M.; Sarcletti, M.; Zemann, A. Capillary Electrophoretic Separation of Protease Inhibitors Used in Human Immunodeficiency Virus Therapy. J. Chromatogr. A. 2001, 922(1-2), 313–320.
   PubMed Web of Science ®Google Scholar
• Pereira, E.; Micke, G.; Tavares, M. Determination of Antiretroviral Agents in Human Serum by Capillary Electrophoresis. J. Chromatogr A. 2005, 1091(1-2), 169–176.
   PubMed Web of Science ®Google Scholar
• Fan, B.; Stewart, J. Determinations of Zidovudine/Didanosine/Nevirapine and Zidovudine/Didanosine/Ritonavir in Human Serum by Micellarelectrokinetic Chromatography. J. Pharmaceut Biomed. 2002, 30(4), 955–960.
   PubMed Web of Science ®Google Scholar
• Carvalho, A.; El-Attug, M.; Zayed, S.; Hove, E.; Duppen, J.; Hoogmartens J.; Schepdael, A. Micellarelectrokinetic Chromatography Method Development for Determination of Impurities in Ritonavir. J. Pharmaceut. Biomed. 2010, 53(5), 1210–1216.
   PubMed Web of Science ®Google Scholar
• Gutleben, W.; Scherer, K.; Tuan, N.; Stoiber, H.; Dierich, M.; Zemann, A. Simultaneous Separation of 11 Protease and Reverse Transcriptase Inhibitors for Human Immunodeficiency Virus Therapy by Co-Electroosmotic Capillary Zone Electrophoresis. J. Chromatogr. A. 2002, 982(1), 153–161.
   PubMed Web of Science ®Google Scholar
• Rao, B.; Vidyadhara, S.; Babu, R.; Kumar, B.; Kumar, G. Analytical Method Development and Validation for Simultaneous Estimation of Lopinavir and Ritonavir by RP-HPLC. IJRDPL. 2014, 3(4), 1074–1079.
   Google Scholar
• Pabolu, H.; Binginapalli, B.; Konidala, S. New Validated RP-HPLC Method for the Determination of Ritonavir in Bulk and Pharmaceutical Dosage Form. Int. J. Pharm. Pharm. Sci. 2013, 5(4), 556–559.
   Google Scholar
• Kumar, K.; Sudhakar, M.; Reddy, Y.; Malleshwari, P.; Hafeez, S. RP-HPLC Method Development and Validation for Simultaneous Estimation of Lopinavir and Ritonavir in Dosage Form and in Plasma. Int. J. Pharma Res. Rev. 2014, 3(9), 1–8.
   Google Scholar
• Hiremath, S.; Bhirud, C. Development and Validation of a Stability Indicating HPLC Method for the Simultaneous Analysis of Lopinavir and Ritonavir in Fixed-Dose Combination Tablets. J. TaibahUniv. Sci. 2015, 10(3), 271–277.
   Google Scholar
• Usami, Y.; Oki, T.; Nakai, M.; Sagisaka, M.; Kaneda, T. A Simple HPLC Method for Simultaneous Determination of Lopinavir, Ritonavir and Efavirenz. Chem. Pharm. Bull. 2003, 51(6), 715–718.
   PubMed Web of Science ®Google Scholar
• Chiranjeevi, K.; Channabasavaraj, K. Development and Validation of RP-HPLC Method for Quantitative Estimation of Ritonavir in Bulk and Pharmaceutical Dosage Forms. Int. J. Pharm. Sci. Res. 2011, 2(3), 596–600.
   Google Scholar
• Killi, G.; Maddinapudi, R.; Dinakaran, S.; Harani A. A Novel Validated UPLC Method for Quantitation of Lopinavir and Ritonavir in Bulk Drug and Pharmaceutical Formulation with Its Impurities. Braz. J. Pharm. Sci. 2014, 50(2), 301–308.
   Web of Science ®Google Scholar
• Huang, J.; Gautam, N.; Bathena, S.; Roy, U.; McMillan, J.; Gendelman, H.; Alnouti, Y. UPLC–MS/MS Quantification of Nanoformulated Ritonavir, Indinavir, Atazanavir, and Efavirenz in Mouse Serum and Tissues. J. Chromatogr. B. 2011, 879(23), 2332–2338.
   PubMed Web of Science ®Google Scholar
• Venugopal, N.; VijayaBhaskar Reddy, A.; Madhavi, G. Development and Validation of a Systematic UPLC–MS/MS Method for Simultaneous Determination of Three Phenol Impurities in Ritonavir. J. Pharm. and Biomed. Anal. 2014, 90(1), 127–133.
   PubMedGoogle Scholar
• Mishra, T.; Shrivastav, P. Validation of Simultaneous Quantitative Method of HIV Protease Inhibitors Atazanavir, Darunavir and Ritonavir in Human Plasma by UPLC-MS/MS. Sci. World J. 2014, 2014(1), 1–12.
   Google Scholar
• Mishra, T.; Kurani, H.; Singhal, P.; Shrivastav, P. Simultaneous Quantitation of HIV-Protease Inhibitors Ritonavir, Lopinavir and Indinavir in Human Plasma by UPLC-ESI-MS-MS. J. Chromatogr. Sci. 2012, 50(7), 625–635.
   PubMed Web of Science ®Google Scholar
• Koppala, S.; Panigrahi, B.; Raju, S.; Padmaja Reddy, K.; Ranga Reddy, V.; Anireddy, J. Development and Validation of a Simple, Sensitive, Selective and Stability-Indicating RP-UPLC Method for the Quantitative Determination of Ritonavir and Its Related Compounds. J. Chromatogr. Sci. 2014, 53(5), 662–675.
   PubMed Web of Science ®Google Scholar
• Hendrikx. J.; Hillebrand, M.; Thijssen, B.; Rosing, H.; Schinkel, A.; Schellens, J.; et al. A Sensitive Combined Assay for the Quantification of Paclitaxel, Docetaxel and Ritonavir in Human Plasma Using Liquid Chromatography Coupled with Tandem Mass Spectrometry. J. Chromatogr. B. 2011, 879(28), 2984–2990.
   PubMed Web of Science ®Google Scholar
• Rezk, N.; White, N.; Bridges, A.; Abdel-Megeed, M.; Mohamed, T.; Moselhy, S.; Kashuba, A. Studies on Antiretroviral Drug Concentrations in Breast Milk: Validation of a Liquid Chromatography-Tandem Mass Spectrometric Method for the Determination of 7 Anti-Human Immunodeficiency Virus Medications. Ther Drug Monit. 2008, 30(5), 611–619.
   PubMed Web of Science ®Google Scholar
• Yao, Y.; Sun, J.; Chen, J.; Liu, X.; Lu, H.; Zhang, L. LC-MS/MS Method for Simultaneous Quantification of Lopinavir and Ritonavir in Human Plasma. Yao XueXueBao. 2010, 45(2), 279–282.
   PubMedGoogle Scholar
• Rao, R.; Ramachandra, B.; Vali, R.; Raju, S. LC–MS/MS Studies of Ritonavir and Its Forced Degradation Products. J. Pharmaceut. Biomed. 2010, 53(4), 833–842.
   PubMed Web of Science ®Google Scholar
• Damaramadugu, R.; Inamadugu, J.; Kanneti, R.; Polagani, S.; Ponneri, V. Simultaneous Determination of Ritonavir and Lopinavir in Human Plasma After Protein Precipitation and LC-MS-MS. Chromatographia. 2010, 71(9-10), 815–824.
   Web of Science ®Google Scholar
• Koehn, J.; Ho, R. Novel Liquid Chromatography-Tandem Mass Spectrometry Method for Simultaneous Detection of Anti-HIV Drugs Lopinavir, Ritonavir, and Tenofovir in Plasma. Antimicrob. Agents Ch. 2014, 58(5), 2675–2680.
   PubMed Web of Science ®Google Scholar
• Burugula, L.; Pilli, N.; Makula, A.; Lodagala, D.; Kandhagatla, R. Simultaneous Determination of Ritonavir and Atazanavir in Human Plasma by LC - MS/MS and Its Pharmacokinetic Application. Am. J. Pharm. Tech. Res. 2012, 2(4), 559–571.
   Google Scholar
• Abdelhay, M.; Gazy, A.; Shaalan, R.; Ashour, H. Validated Stability-Indicating HPLC and HPTLC Methods for the Determination of Ritonavir in Bulk Powder and in Capsules. J. Food Drug Anal. 2012, 20(4), 963–973.
   Web of Science ®Google Scholar
• Patil, P.; Wankhede, S.; Chaudhari, P. Stability-Indicating HPTLC Method for Simultaneous Determination of Lopinavir and Ritonavir in Bulk and Pharmaceutical Dosage Form. WJPPS. 2014, 3(6), 1613–1629.
   Google Scholar
• Al-zoman, N. Z.; Maher, H. M.; Al-subaie, A. Simultaneous Determination of Newly Developed Antiviral Agents in Pharmaceutical Formulations by HPLC-DAD. Chem. Cent. J. 2017, 11, 1.1–8.
   Web of Science ®Google Scholar
• Ariaudo, A.; Favata, F.; De Nicolò, A.; Simiele, M.; Paglietti, L.; Boglione, L.; Cardellino, C. S.; Carcieri, C.; Di Perri, G.; D’Avolio, A. A UHPLC–MS/MS Method for the Quantification of Direct Antiviral Agents Simeprevir, Daclatasvir, Ledipasvir, Sofosbuvir/GS-331007, Dasabuvir, Ombitasvir and Paritaprevir, Together with Ritonavir, in Human Plasma. J. Pharm. Biomed. Anal. 2016, 125(1), 369–375.
   PubMedGoogle Scholar
• Ocque, A.; Hagler, C.; Difrancesco, R.; Woolwine-Cunningham, Y.; Bednasz, C.; Morse, G.; Talal, A. Development and Validation of a UPLC–MS/MS Method for the Simultaneous Determination of Paritaprevir and Ritonavir in Rat Liver. Bioanalysis. 2016, 8(13), 1353–1363.
   PubMed Web of Science ®Google Scholar
• Sultan, M.; Maher, H.; Alzoman, N.; Alshehri, M.; Rizk, M.; Elshahed, M.; Olah, IV. Capillary Electrophoretic Determination of Antimigraine Formulations Containing Caffeine, Ergotamine, Paracetamol and Domperidone or Metoclopramide. J. Chromatogr. Sci. 2012, 51(6), 502–510.
   PubMed Web of Science ®Google Scholar
• Haj-Ali, D.; Hamdan, I. Development of a Capillary Electrophoresis Method for the Determination of Orphenadrine Citrate in Tablets in the Presence of Paracetamol. Saudi Pharm. J. 2010, 18(4), 233–237.
   PubMedGoogle Scholar
• Azhagvuel, S.; Sekar, R. Method Development and Validation for the Simultaneous Determination of Cetirizine Dihydrochloride, Paracetamol, and Phenylpropanolamine Hydrochloride in Tablets by Capillary Zone Electrophoresis. J. Pharm. Biomed. Anal. 2007, 43(3), 873–878.
   PubMed Web of Science ®Google Scholar
• ICH. Q2(R1): Validation of Analytical Procedure: Text and Methodology [Internet]. ICH Guideline. 2005 [cited 14 April 2017]. Available from: https://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Quality/Q2_R1/Step4/Q2_R1__Guideline.pdf
   Google Scholar
• Miller, J. N.; Miller, J. C. Statistics and Chemometrics for Analytical Chemistry. 5th ed. Pearson Prentice Hall: Harlow, England; New York, 2005.
   Google Scholar